138 related articles for article (PubMed ID: 25588366)
1. The improvement of the dissolution rate of ziprasidone free base from solid oral formulations.
Zakowiecki D; Cal K; Kaminski K; Adrjanowicz K; Swinder L; Kaminska E; Garbacz G
AAPS PharmSciTech; 2015 Aug; 16(4):922-33. PubMed ID: 25588366
[TBL] [Abstract][Full Text] [Related]
2. In vitro and in vivo characterization of amorphous, nanocrystalline, and crystalline ziprasidone formulations.
Thombre AG; Shah JC; Sagawa K; Caldwell WB
Int J Pharm; 2012 May; 428(1-2):8-17. PubMed ID: 22349051
[TBL] [Abstract][Full Text] [Related]
3. Solid nanocrystalline dispersions of ziprasidone with enhanced bioavailability in the fasted state.
Thombre AG; Caldwell WB; Friesen DT; McCray SB; Sutton SC
Mol Pharm; 2012 Dec; 9(12):3526-34. PubMed ID: 23075293
[TBL] [Abstract][Full Text] [Related]
4. Silica encapsulated lipid-based drug delivery systems for reducing the fed/fasted variations of ziprasidone in vitro.
Dening TJ; Rao S; Thomas N; Prestidge CA
Eur J Pharm Biopharm; 2016 Apr; 101():33-42. PubMed ID: 26812284
[TBL] [Abstract][Full Text] [Related]
5. Effect of Coadministered Water on the In Vivo Performance of Oral Formulations Containing N-Acetylcysteine: An In Vitro Approach Using the Dynamic Open Flow-Through Test Apparatus.
Sager M; Schneider F; Jedamzik P; Wiedmann M; Schremmer E; Koziolek M; Weitschies W
Mol Pharm; 2017 Dec; 14(12):4272-4280. PubMed ID: 29064257
[TBL] [Abstract][Full Text] [Related]
6. Preparation and evaluation of ziprasidone-phospholipid complex from sustained-release pellet formulation with enhanced bioavailability and no food effect.
Miao Y; Chen G; Ren L; Ouyang P
J Pharm Pharmacol; 2016 Feb; 68(2):185-94. PubMed ID: 26748446
[TBL] [Abstract][Full Text] [Related]
7. Formulation development and systematic optimization of stabilized ziprasidone hydrochloride capsules devoid of any food effect.
Banerjee S; Shankar KR; Prasad Y R
Pharm Dev Technol; 2016 Nov; 21(7):775-786. PubMed ID: 26135230
[TBL] [Abstract][Full Text] [Related]
8. Nanocrystal-silica-lipid hybrid particles for the improved oral delivery of ziprasidone in vitro.
Meola TR; Dening TJ; Prestidge CA
Eur J Pharm Biopharm; 2018 Aug; 129():145-153. PubMed ID: 29857135
[TBL] [Abstract][Full Text] [Related]
9. Effect of cyclodextrin derivation and amorphous state of complex on accelerated degradation of ziprasidone.
Hong J; Shah JC; Mcgonagle MD
J Pharm Sci; 2011 Jul; 100(7):2703-16. PubMed ID: 21283987
[TBL] [Abstract][Full Text] [Related]
10. A Combined Utilization of Plasdone-S630 and HPMCAS-HF in Ziprasidone Hydrochloride Solid Dispersion by Hot-Melt Extrusion to Enhance the Oral Bioavailability and No Food Effect.
Xue X; Chen G; Xu X; Wang J; Wang J; Ren L
AAPS PharmSciTech; 2019 Jan; 20(1):37. PubMed ID: 30604142
[TBL] [Abstract][Full Text] [Related]
11. Controlled release of ziprasidone solid dispersion systems from osmotic pump tablets with enhanced bioavailability in the fasted state.
Yanfei M; Guoguang C; Lili R; Pingkai O
Drug Dev Ind Pharm; 2015; 41(8):1353-62. PubMed ID: 25138348
[TBL] [Abstract][Full Text] [Related]
12. Bio-relevant dissolution testing of hard capsules prepared from different shell materials using the dynamic open flow through test apparatus.
Garbacz G; Cadé D; Benameur H; Weitschies W
Eur J Pharm Sci; 2014 Jun; 57():264-72. PubMed ID: 24021609
[TBL] [Abstract][Full Text] [Related]
13. Analysis of the enhanced oral bioavailability of fenofibrate lipid formulations in fasted humans using an in vitro-in silico-in vivo approach.
Fei Y; Kostewicz ES; Sheu MT; Dressman JB
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1274-84. PubMed ID: 23500116
[TBL] [Abstract][Full Text] [Related]
14. Preparation of an amorphous sodium furosemide salt improves solubility and dissolution rate and leads to a faster Tmax after oral dosing to rats.
Nielsen LH; Gordon S; Holm R; Selen A; Rades T; Müllertz A
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):942-51. PubMed ID: 24075980
[TBL] [Abstract][Full Text] [Related]
15. Development of Nanocrystal Ziprasidone Orally Disintegrating Tablets: Optimization by Using Design of Experiment and In Vitro Evaluation.
Tashan E; Karakucuk A; Celebi N
AAPS PharmSciTech; 2020 Apr; 21(3):115. PubMed ID: 32296987
[TBL] [Abstract][Full Text] [Related]
16. Molecular dynamics of the cryomilled base and hydrochloride ziprasidones by means of dielectric spectroscopy.
Kaminski K; Adrjanowicz K; Wojnarowska Z; Grzybowska K; Hawelek L; Paluch M; Zakowiecki D; Mazgalski J
J Pharm Sci; 2011 Jul; 100(7):2642-57. PubMed ID: 21271564
[TBL] [Abstract][Full Text] [Related]
17. Pharmacoscintigraphy studies to assess the feasibility of a controlled release formulation of ziprasidone.
Thombre AG; Shamblin SL; Malhotra BK; Connor AL; Wilding IR; Caldwell WB
J Control Release; 2015 Sep; 213():10-17. PubMed ID: 26130417
[TBL] [Abstract][Full Text] [Related]
18. New formulation approaches to improve solubility and drug release from fixed dose combinations: case examples pioglitazone/glimepiride and ezetimibe/simvastatin.
Taupitz T; Dressman JB; Klein S
Eur J Pharm Biopharm; 2013 May; 84(1):208-18. PubMed ID: 23246797
[TBL] [Abstract][Full Text] [Related]
19. Determination of Ziprasidone in pharmaceutical formulations by capillary zone electrophoresis.
Farina C; Kremser L; Raggi MA; Kenndler E
J Pharm Biomed Anal; 2008 Feb; 46(3):471-6. PubMed ID: 18155379
[TBL] [Abstract][Full Text] [Related]
20. In vitro dissolution methodology, mini-Gastrointestinal Simulator (mGIS), predicts better in vivo dissolution of a weak base drug, dasatinib.
Tsume Y; Takeuchi S; Matsui K; Amidon GE; Amidon GL
Eur J Pharm Sci; 2015 Aug; 76():203-12. PubMed ID: 25978875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
